Paxman AB (publ) (PAX.ST)
SEK 64.4
(2.55%)
SEK 64.4
(2.55%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 31.22 Million SEK | 92.74% |
| 2022 | 16.17 Million SEK | 459.65% |
| 2021 | 2.89 Million SEK | 380.52% |
| 2020 | -1.04 Million SEK | -114.52% |
| 2019 | 5.79 Million SEK | 7994.44% |
| 2018 | -95 Thousand SEK | 98.27% |
| 2017 | -5.19 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 14.76 Million SEK | 25.79% |
| 2024 Q1 | 11.74 Million SEK | 23.64% |
| 2023 Q3 | 12.99 Million SEK | 114.83% |
| 2023 FY | - SEK | 92.74% |
| 2023 Q1 | 2.68 Million SEK | -79.65% |
| 2023 Q2 | 6.05 Million SEK | 125.33% |
| 2023 Q4 | 9.49 Million SEK | -26.94% |
| 2022 Q1 | -2.88 Million SEK | -167.9% |
| 2022 Q4 | 13.19 Million SEK | 137.33% |
| 2022 Q3 | 5.55 Million SEK | 1554.17% |
| 2022 Q2 | 336 Thousand SEK | 111.65% |
| 2022 FY | - SEK | 459.65% |
| 2021 Q1 | 409 Thousand SEK | 112.36% |
| 2021 Q2 | -479 Thousand SEK | -217.11% |
| 2021 Q3 | -1.28 Million SEK | -167.43% |
| 2021 Q4 | 4.24 Million SEK | 431.46% |
| 2021 FY | - SEK | 380.52% |
| 2020 Q1 | 5.72 Million SEK | 2195.97% |
| 2020 Q3 | -156 Thousand SEK | -116.35% |
| 2020 Q4 | -3.3 Million SEK | -2020.51% |
| 2020 FY | - SEK | -114.52% |
| 2020 Q2 | 954 Thousand SEK | -83.33% |
| 2019 Q4 | -273 Thousand SEK | -106.18% |
| 2019 FY | - SEK | 7994.44% |
| 2019 Q1 | 882 Thousand SEK | 208.09% |
| 2019 Q2 | 2.33 Million SEK | 164.51% |
| 2019 Q3 | 4.41 Million SEK | 89.33% |
| 2018 Q3 | 1.11 Million SEK | 368.2% |
| 2018 Q4 | -816 Thousand SEK | -172.92% |
| 2018 Q2 | 239 Thousand SEK | 137.46% |
| 2018 FY | - SEK | 98.27% |
| 2018 Q1 | -638 Thousand SEK | 85.61% |
| 2017 FY | - SEK | 0.0% |
| 2017 Q1 | -334 Thousand SEK | 0.0% |
| 2017 Q2 | 909 Thousand SEK | 372.16% |
| 2017 Q3 | -1.62 Million SEK | -278.22% |
| 2017 Q4 | -4.43 Million SEK | -173.7% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 140.493% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 92.418% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 92.418% |
| Arcoma AB | 6.24 Million SEK | -399.824% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 134.706% |
| BICO Group AB (publ) | 322.3 Million SEK | 90.311% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 52.668% |
| CellaVision AB (publ) | 207.24 Million SEK | 84.931% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 145.652% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 211.76% |
| C-Rad AB (publ) | 48.9 Million SEK | 36.142% |
| Duearity AB (publ) | -24.77 Million SEK | 226.03% |
| Dignitana AB (publ) | -264 Thousand SEK | 11929.167% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 135.609% |
| Getinge AB (publ) | 5.92 Billion SEK | 99.473% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 146.437% |
| Iconovo AB (publ) | -35.33 Million SEK | 188.379% |
| Integrum AB (publ) | 8.76 Million SEK | -256.433% |
| Luxbright AB (publ) | -23.86 Million SEK | 230.847% |
| Mentice AB (publ) | 28.87 Million SEK | -8.16% |
| OssDsign AB (publ) | -122.02 Million SEK | 125.593% |
| Promimic AB (publ) | -3.68 Million SEK | 947.693% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 120.749% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 160.254% |
| ScandiDos AB (publ) | -13.35 Million SEK | 333.82% |
| Sectra AB (publ) | 615.06 Million SEK | 94.923% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 160.435% |
| Senzime AB (publ) | -118.82 Million SEK | 126.282% |
| SpectraCure AB (publ) | -20.96 Million SEK | 248.929% |
| Stille AB | 56.04 Million SEK | 44.275% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 100.981% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 75.327% |